Regenhu, a bioprinting company based in rural Fribourg, complements medieval towns, deep lakes and Swiss Alpine traditions. It is currently developing the most advanced 3D printers in Europe and forming alliances with research institutes to quickly become a leader in this emerging field. Recent advances have provided them with tools for fabricating bionic tissue structures, tissue growth techniques and drug discovery.
Just over a month ago, researchers at Tel Aviv University used Regenhu's 3D printer to make heart patches and cellular hearts for patients with heart failure, and used patient-specific hydrogels as bio-ink to avoid rejection. Together with their partners, Regenhu is an advanced bioprint company in the region, participating in projects such as the University of Glasgow, Scotland, the National Institutes of Health and the Davos AO Institute. Looking forward to the next 10 to 20 years, CEO and founder Mark Seiner firmly believes that the future is regenerative medicine, and their printers can make 3D printing of implantable living organs a reality.
Regenhu's story started in 2007 as a pioneer in the field of bioprinting, when bioprinting companies were just beginning to fill the much-needed gaps in medical and research fields. There were three bioprinting companies, including Organovo in San Diego. Regenhu chose to take advantage of the potential of bio-3D printing in the field of treatment, and established a unique corporate structure with academic partners and affiliates that developed innovative transformed products into the medical environment.
He explained that his vision was to use 3D printing to create a three-dimensional biological environment in which cells, biological activities and extracellular biomaterials could be combined to interact with cells and create physiological pathways that mimic those found in natural tissues and organs.
At that time, with the concept put forward by Sener, the scientific community was still skeptical about Printing cells and proteins.
"Therefore, Regenhu has to face the challenges of difficulty and resource consumption in order to prove the printability and viability of cells after printing," he said.
There are many other questions, including whether cells can survive or even maintain their shape. This was successfully achieved in 2009 and spawned a new paper towel printing industry. Nevertheless, the bioprint industry is far from knowing how all the applications of these machines work.
Regenhu has done a lot to lay the foundation for bioprinting in Europe and overcome doubts. In collaboration with Usula Graf Hausner, a biologist and chemist specializing in tissue engineering cell culture at the University of Applied Sciences of Zurich, he worked with primitive human cells and human tissue creation in the hope of creating a tissue engineering center for drug development at the University.
But it's not easy to deal with living cells. Initially, cells printed in 3-D did not survive. Although there are many cell-compatible biomaterials on the market, none of them solidified fast enough after printing. So the two scientists added biologist Marcus Riemann, who had the idea of developing a chemically defined bio-ink, which made it possible to print the material.
Since its inception, the company has grown substantially, serving as a capital equipment provider and providing cutting-edge bioprinting instruments to leading scientific and clinical institutions in the world. Some of their customers include L'Oreal and Novartis Pharmaceuticals. Regenhu uses cells, proteins and extracellular matrix to produce biomass for different tissue types, and develops a unique knowledge of the components and conditions required to drive the formation of specific tissues. This knowledge is the result of a number of research work carried out with academic and industrial research institutions.
"The evolution of biology is a rather slow process, and scientists are still learning and understanding the basic knowledge behind science. Therefore, our task is to support their discoveries and provide specialized scientific instruments. We hope that in the next decade, they will find ways to make simple tissues, and believe that the future of bioprinting will be drug discovery, personalized medicine, precision medicine, and, of course, organ transplantation, "Sener explained.
Now there are more than 40 well-known bioprinting companies in Europe, Regenhu is still growing. In addition, in order to overcome the growing demand for dental 3D printing applications, Regenhu and the Academy of Dentistry of the University of Geneva co-founded Vivos Dental, a spin-off company, to develop, manufacture and sell oral bone enhancement solutions, such as its patented Osteo Flux *, a synthetic bone transplant for oral 3D printing. Bone augmentation and bone regeneration are still developing. This may be a good choice for patients who do not have enough bone for dental implants, so Vivos Dental's goal is to increase bone mass to provide a good attachment area. This is an exciting moment for dental 3D printing, especially when it is expected to become a market for more than $4 billion worth of dental prostheses, orthodontic equipment and other dental components.
Bioprinting is no longer an early technology, it has transited to the clinical environment, which is why Regenhu developed bio-3D printing. Regenhu developed not only a bioprint, but also a technology platform, which can develop with the needs of researchers, and provide the best tools, which can be integrated into a manufacturing process. Jehol's machine is used to print skin patches for transplantation to burn patients, Novartis Pharmaceuticals has developed muscle tissue models, and even print cartilage for joint repair.
A few years ago, Regenhu realized that software technology was also a very important tool for bioprinting applications, enabling scientists to tap their potential, so they invested in software tools, such as Biocad, which allowed researchers without engineering background to draw hierarchically according to the organization they wanted. Biocam can import 3D data from medical scanners and modify the 3D printing structure.
Last year, Regenhu appointed Wako Automation, a San Diego-based supplier of laboratory automation solutions, as part of their U.S. official system integrator effort to expand new markets, customers and researchers.
For Regenhu, all this contributes to the biotechnology industry by coordinating projects with academia, pharmaceutical users, biotechnology institutes and cosmetics companies. This is part of their discovery of evolution and a way to learn how to control cell biology, leading to some of the most popular developments in regeneration and therapeutic medicine, such as biomimetic tissue construction, in order to be as close as possible to in vitro environmental simulations.
Regenhu, like other bioprinting pioneers and pioneers, is looking for NSWERS, despite the global collaboration and the upsurge in ecosystems of development partners and users in the biomanufacturing industry, but in areas such as the development of vascularization to help create functional organs remains challenging. It may take several years for researchers to make new progress in bioprinting.
source from: https://creality3dpro.store/